Lung cancer • 4: Chemotherapy for non-small cell lung cancer: the end of the beginning

Cullen, M.
April 2003
Thorax;Apr2003, Vol. 58 Issue 4, p352
Academic Journal
Charts the development of chemotherapy in non-small cell lung cancer (NSCLC) and discusses its role in advanced disease, as a neoadjuvant therapy before definitive surgery, as an adjuvant after surgery, in subgroups of patients defined by age and performance status, and in patients who relapse after a response to primary chemotherapy. Chemotherapeutic agents; Chemotherapy for elderly patients.


Related Articles

  • Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Bennouna, J.; Breton, J.-L.; Tourani, J.-M.; Ottensmeier, C.; O'Brien, M.; Kosmidis, P.; Huat, T. E.; Pinel, M.-C.; Colin, C.; Douillard, J.-Y. // British Journal of Cancer;5/22/2006, Vol. 94 Issue 10, p1383 

    A multicentre, single-arm, phase II trial designed to determine the efficacy of single-agent vinflunine in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum-based regimen. The objectives were to assess efficacy in terms of tumour response rate (primary...

  • Erlotinib prolongs survival of patients with NSCLC.  // Formulary;Nov2004, Vol. 39 Issue 11, p529 

    Reports on a study evaluating the use of the investigational agent erlotinib to treat non-small-cell lung cancer. Survival rates; Safety profile; Treatment outcomes.

  • Gefitinib approved for lung cancer.  // WHO Drug Information;2003, Vol. 17 Issue 2, p102 

    Reports that the U.S. Food and Drug Administration (FDA) has announced the approval of gefitinib tablets as a single agent treatment for patients with advanced non small-cell lung cancer. Approval of gefitinib as a treatment for patients whose cancer has continued to progress despite treatment...

  • Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Hayashi, H.; Okamoto, I.; Morita, S.; Taguri, M.; Nakagawa, K. // Annals of Oncology;Jun2012, Vol. 23 Issue 6, p1537 

    Background: Given the growing number of drugs available for non-small-cell lung cancer (NSCLC), an effect of first-line chemotherapy on overall survival (OS) might be confounded by subsequent therapies. We examined the relation between postprogression survival (PPS) and OS in phase III trials of...

  • Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer. Wada, M.; Yamamoto, M.; Ryuge, S.; Nagashima, Y.; Hayashi, N.; Maki, S.; Otani, S.; Katono, K.; Takakura, A.; Yanaihara, T.; Igawa, S.; Yokoba, M.; Mitsufuji, H.; Kubota, M.; Katagiri, M.; Masuda, N. // Cancer Chemotherapy & Pharmacology;Apr2012, Vol. 69 Issue 4, p1005 

    Background: In this phase II clinical trial, we evaluated the efficacy and safety of S-1 monotherapy in patients with previously treated advanced non-small-cell lung cancer (NSCLC). We also measured plasma concentrations of 5-fluorouracil (5-FU) and 5-chloro-2,4-dihydroxypyridine components of...

  • Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). Kosmidis, P. A.; Fountzilas, G.; Eleftheraki, A. G.; Kalofonos, H. P.; Pentheroudakis, G.; Skarlos, D.; Dimopoulos, M. A.; Bafaloukos, D.; Pectasides, D.; Samantas, E.; Boukovinas, J.; Lambaki, S.; Katirtzoglou, N.; Bakogiannis, C.; Syrigos, K. N. // Annals of Oncology;Apr2011, Vol. 22 Issue 4, p827 

    Background: Paclitaxel (Taxol) and vinorelbine have shown synergism of cytotoxic effects in vitro and clinical activity in phase I and II studies. This combination was compared prospectively with the paclitaxel/gemcitabine regimen in non-operable non-small-cell lung cancer.Patients and methods:...

  • Schering-Plough loses momentum on anticancer drug, but set to bounce back. Mirasol, Feliza // Chemical Market Reporter;2/16/2004, Vol. 265 Issue 7, p9 

    Reports on pharmaceutical firm Schering-Plough Corp.'s termination of clinical trials of its anticancer drug Sarasar for non-small-cell lung cancer. Reasons of the company for discontinuing trials; Impact of the setback on the company's business outlook.

  • Cell Therapeutics to advance polyglutamate camptothecin to phase II clinical trials.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p12 

    Reports on the announcement of Cell Therapeutics of its plan to begin phase I and II studies of its novel camptothecin polymer conjugate in combination with standard chemotherapy in colorectal cancer and as a single agent in small cell lung cancer, in 2004. Recognition of camptothecin as one of...

  • New drug demonstrates favorable toxicity profile and efficacy in previously treated non-small cell lung cancer patients.  // PharmaWatch: Cancer;August 2003, Vol. 2 Issue 8, p17 

    Announces that Allos Therapeutics has published results from a clinical study conducted by researchers at the Memorial Sloan-Kettering Cancer Center on PDX as treatment for non-small cell lung cancer. Response rate and symptomatic benefit from the drug.

  • Randomized Trial of Gefitinib for Advanced Lung Cancer Closed Early. Zielinski, Sarah L.; Travis, Kate // JNCI: Journal of the National Cancer Institute;5/18/2005, Vol. 97 Issue 10, p712 

    Reports on Southwest Oncology Group researchers' termination of a phase III randomized clinical trial of gefitinib versus placebo following chemotherapy and radiation for patients with non-small-cell lung cancer that had spread only to nearby tissues or lymph nodes. Number of patients enrolled...


Read the Article


Sign out of this library

Other Topics